What is the primary goal of Medtronic's new operating model?

The primary goal is to make Medtronic a more nimble and competitive organization by accelerating innovation, enhancing the customer experience, driving revenue growth, and winning market share, while simultaneously improving operational efficiency through leveraging its enterprise scale.

What are the expected financial impacts of this restructuring program?

Medtronic expects to incur pre-tax costs of approximately $400-$450 million for the Simplification Restructuring Program, with the majority recognized by the end of fiscal year 2022. However, it anticipates significant annualized cost savings of $450-$475 million by fiscal year 2023, which will be reinvested to drive future revenue growth and EPS.

When will this new operating model be fully implemented?

The company will begin transitioning to the new model in its fiscal third quarter of 2021 and expects it to be fully effective at the start of its fiscal fourth quarter of 2021.

Will Medtronic's external financial reporting segments change as a result of this reorganization?

Medtronic is currently assessing the impact of these changes on its external reporting segments and will provide an update, if changes are necessary, prior to the start of its fiscal fourth quarter of 2021.

MDT 8-K: Regulation FD

Summary

Medtronic plc (MDT) announced a significant organizational overhaul via a new operating model designed to enhance agility, accelerate innovation, and drive market share growth. This restructuring involves creating highly focused, accountable, and empowered Operating Units (OUs) organized around specific therapy areas. These OUs will have direct P&L responsibility, control over R&D and sales in key markets, moving Medtronic closer to its customers and streamlining decision-making. Simultaneously, enterprise-level functions like global manufacturing and supply chain will be consolidated to leverage scale and drive efficiencies. The company expects to incur restructuring costs of approximately $400-$450 million, with the majority recognized by the end of fiscal year 2022. However, this program is projected to yield significant annualized cost savings of $450-$475 million by fiscal year 2023, which Medtronic intends to reinvest to fuel future revenue growth and enhance long-term EPS. The transition is slated to begin in Q3 FY21 and be fully effective at the start of Q4 FY21, with a potential update on external segment reporting to follow.

Key Highlights

1Medtronic is implementing a new operating model to become more nimble and competitive, focusing on accelerating innovation, customer experience, and market share.
2The company is reorganizing into focused, accountable, and empowered Operating Units (OUs) based on therapy areas, granting them P&L responsibility and control over R&D and sales in larger geographies.
3Enterprise-level functions such as global manufacturing and supply chain will be consolidated to achieve greater efficiencies and leverage scale.
4A Simplification Restructuring Program is initiated, with estimated pre-tax costs of $400-$450 million, largely incurred by the end of FY22.
5The restructuring is expected to generate annualized cost savings of $450-$475 million by FY23, intended for reinvestment in growth initiatives.
6The new operating model will begin transitioning in fiscal Q3 2021 and be fully effective at the start of fiscal Q4 2021.
7Medtronic plans to discuss the new operating model at its virtual Investor Day on October 14, 2020.

Medtronic plc 8-K Report, Regulation FD Disclosure (Sep 1, 2020)

Summary

Key Highlights

Frequently Asked Questions